Living with itHR-positive / HER2-negative breast cancer

Back to the HR-positive / HER2-negative breast cancer hub →47 questions · 6 red cards

The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask.

Living with it

top

The first 60 days →Appointment prep sheet →Side effects →Help with costs →

Decisions you may face

13 with more than one option · full decision page →

One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.

Early stage3 Metastatic first line3 Metastatic second line5 Endocrine-resistant3 Screening and diagnosis3 Early stage, deciding on chemotherapy2 Early stage, adjuvant endocrine therapy3 Early stage, high risk: adjuvant CDK4/63 Early stage, extended and adjuvant SERD (emerging)Metastatic, first line4 Metastatic, molecular progression on first line Metastatic, second line by genotype5 Metastatic, endocrine-resistant: ADC before chemotherapy3 Metastatic, chemotherapy and later lines3 Bone-predominant disease and survivorship2

Red cards

From the labels and guidelines behind the standard of care. Your team's thresholds win.

Emergency services now
Blood clot (tamoxifen and others)
A swollen painful calf, or sudden breathlessness with chest pain; the tamoxifen boxed warning covers pulmonary embolism and stroke.
Camizestrant Elacestrant Giredestrant Goserelin / leuprolide (ovarian function suppression)Imlunestrant Letrozole (and other aromatase inhibitors)Tamoxifen source
Emergency services now
Fainting or palpitations (ribociclib)
Fainting, dizziness or an irregular heartbeat; QT prolongation is a labelled warning and ECGs are checked in the first cycles.
Abemaciclib Palbociclib Ribociclib source
Emergency services now
Skin reaction
Blisters, peeling, or sores in the mouth or eyes with a rash. Enfortumab vedotin carries a boxed warning for Stevens-Johnson syndrome and toxic epidermal necrolysis, mostly in the first cycle.
Datopotamab deruxtecan Sacituzumab govitecan Trastuzumab deruxtecan source
Emergency services now
Blood clot
A swollen painful calf, or sudden breathlessness with chest pain; venous thromboembolism including pulmonary embolism is a labelled warning.
Olaparib Talazoparib source
Emergency services now
Bleeding or bruising
Bleeding that will not stop, black or bloody stools, or unexplained bruising when platelets are expected to be low.
Paclitaxel / nab-paclitaxel source
Call the 24-hour line now
Interstitial lung disease or pneumonitis
Any new or worsening cough, breathlessness or fever. The label says to interrupt treatment for any suspected ILD and to permanently discontinue for grade 2 or higher.
Datopotamab deruxtecan Trastuzumab deruxtecan source

See all on the product pages:Abemaciclib Camizestrant Datopotamab deruxtecan Elacestrant Giredestrant Goserelin / leuprolide (ovarian function suppression)Imlunestrant Letrozole (and other aromatase inhibitors)Olaparib Paclitaxel / nab-paclitaxel Palbociclib Ribociclib Sacituzumab govitecan Talazoparib Tamoxifen Trastuzumab deruxtecan·Printable cards in the navigator

Treatment journeys

What the next twelve months look like, phase by phase, with the decision points.

Stage I-II (early)

Questions to ask

Bring to your appointment

Questions to ask your oncologist about HR-positive / HER2-negative breast cancer

Generated from this cancer's standard of care, biomarkers, and pipeline · 47 questions

Newly diagnosed

What is my exact diagnosis, stage, and grade, and which tests established them?
Why: Everything else follows from an accurate stage and subtype.
Which biomarkers have been tested on my tumour (for example ER/PR, HER2 IHC 0/1+/2+, Ki-67, Oncotype DX / MammaPrint / Prosigna, PIK3CA/AKT1/PTEN), and what were the results?
Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
Which subtype is my cancer, and does that change the recommended treatment?
Why: Recognised subtypes for this cancer include Luminal A, Luminal B, HER2-low.
Is germline (inherited) genetic testing recommended for me or my family?
Why: Inherited variants can change treatment and matter for relatives.

Early stage

For my situation (early stage), which of the standard options do you recommend and why?
Why: Guideline options include: Surgery, radiation, endocrine therapy 5-10 years; chemotherapy if genomic risk high; abemaciclib or ribociclib adjuvant for high-risk.
Am I a candidate for Oncotype DX, Abemaciclib, Ribociclib, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of monarchE and NATALEE apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Metastatic first line

For my situation (metastatic first line), which of the standard options do you recommend and why?
Why: Guideline options include: CDK4/6 inhibitor + aromatase inhibitor or fulvestrant.
Am I a candidate for Palbociclib, Ribociclib, Abemaciclib, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Metastatic second line

For my situation (metastatic second line), which of the standard options do you recommend and why?
Why: Guideline options include: Genotype-directed: capivasertib, inavolisib, alpelisib, everolimus; elacestrant/vepdegestrant if ESR1-mutant; gedatolisib.
Am I a candidate for Capivasertib, Inavolisib, Elacestrant or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Endocrine-resistant

For my situation (endocrine-resistant), which of the standard options do you recommend and why?
Why: Guideline options include: T-DXd (HER2-low/ultralow) before chemotherapy; sacituzumab govitecan or Dato-DXd after chemotherapy.
Am I a candidate for Trastuzumab deruxtecan, Sacituzumab govitecan, Datopotamab deruxtecan, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of DESTINY-Breast06 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Screening and diagnosis

For my situation (screening and diagnosis), which of the standard options do you recommend and why?
Why: Guideline options include: Mammography ± tomosynthesis; supplemental MRI for dense breasts or high risk; core biopsy with ER/PR/HER2/Ki-67; AI-assisted reading being deployed.

Early stage, deciding on chemotherapy

For my situation (early stage, deciding on chemotherapy), which of the standard options do you recommend and why?
Why: Guideline options include: Genomic assay (Oncotype DX RS ≤25 node-negative or postmenopausal 1-3 nodes; MammaPrint low risk) → endocrine therapy alone; premenopausal RS 16-25 or high clinical risk → chemotherapy or OFS-based escalation.
Am I a candidate for Oncotype DX, MammaPrint (70-gene signature), and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of TAILORx and RxPONDER (SWOG S1007) apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Early stage, adjuvant endocrine therapy

For my situation (early stage, adjuvant endocrine therapy), which of the standard options do you recommend and why?
Why: Guideline options include: Postmenopausal: aromatase inhibitor 5-10 years (or tamoxifen → AI switch). Premenopausal: tamoxifen 5-10 years; add OFS (+ AI or tamoxifen) for higher-risk or chemotherapy-treated women (SOFT/TEXT).
Am I a candidate for Letrozole (and other aromatase inhibitors), Tamoxifen, Goserelin / leuprolide (ovarian function suppression), and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of SOFT & TEXT apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Early stage, high risk: adjuvant CDK4/6

For my situation (early stage, high risk: adjuvant cdk4/6), which of the standard options do you recommend and why?
Why: Guideline options include: Abemaciclib 2 years for node-positive high-risk (monarchE); ribociclib 3 years for stage II-III including node-negative high-risk (NATALEE). Palbociclib not effective (PALLAS/PENELOPE-B). Olaparib 1 year if gBRCA (OlympiA).
Am I a candidate for Abemaciclib, Ribociclib, Olaparib, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of monarchE and NATALEE apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Early stage, extended and adjuvant SERD (emerging)

For my situation (early stage, extended and adjuvant serd (emerging)), which of the standard options do you recommend and why?
Why: Guideline options include: Extended AI to 10 years for higher-risk (MA.17R, NSABP B-42); adjuvant giredestrant positive in lidERA (2025, not yet approved); CAMBRIA (camizestrant) and EMBER-4 (imlunestrant) ongoing.
Am I a candidate for Giredestrant, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of lidERA and CAMBRIA-1 & CAMBRIA-2 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Metastatic, first line

For my situation (metastatic, first line), which of the standard options do you recommend and why?
Why: Guideline options include: CDK4/6 inhibitor + aromatase inhibitor (or fulvestrant): ribociclib or abemaciclib preferred where OS data are valued; palbociclib acceptable. Premenopausal: add OFS. For relapse on/within 12 months of adjuvant ET with PIK3CA mutation: inavolisib + palbociclib + fulvestrant (INAVO120).
Am I a candidate for Ribociclib, Abemaciclib, Palbociclib or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of MONALEESA-2 and MONARCH 3 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Metastatic, molecular progression on first line

For my situation (metastatic, molecular progression on first line), which of the standard options do you recommend and why?
Why: Guideline options include: Serial ctDNA; on emergent ESR1 mutation before radiographic progression, switch AI → camizestrant and continue the CDK4/6 inhibitor (SERENA-6; accelerated approval 4 Sep 2026).
Am I a candidate for Camizestrant, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of SERENA-6 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Metastatic, second line by genotype

For my situation (metastatic, second line by genotype), which of the standard options do you recommend and why?
Why: Guideline options include: ESR1-mutant: elacestrant, imlunestrant (± abemaciclib), or vepdegestrant. PIK3CA/AKT1/PTEN: capivasertib + fulvestrant; alpelisib + fulvestrant. Any genotype after CDK4/6: gedatolisib + palbociclib + fulvestrant (PIK3CA-wild-type, 2026); everolimus + exemestane or giredestrant (filed); abemaciclib switch (postMONARCH, modest).
Am I a candidate for Gedatolisib, Elacestrant, Imlunestrant or related drugs, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of EMBER-3 and EMERALD apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Metastatic, endocrine-resistant: ADC before chemotherapy

For my situation (metastatic, endocrine-resistant: adc before chemotherapy), which of the standard options do you recommend and why?
Why: Guideline options include: HER2-low or ultralow (~60%): T-DXd (DESTINY-Breast06 chemotherapy-naive; DESTINY-Breast04 after chemotherapy). HER2-zero: sacituzumab govitecan or Dato-DXd after chemotherapy (TROPiCS-02, TROPION-Breast01).
Am I a candidate for Trastuzumab deruxtecan, Sacituzumab govitecan, Datopotamab deruxtecan, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of DESTINY-Breast06 and DESTINY-Breast04 apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Metastatic, chemotherapy and later lines

For my situation (metastatic, chemotherapy and later lines), which of the standard options do you recommend and why?
Why: Guideline options include: Sequential single-agent chemotherapy (capecitabine, taxanes, eribulin, vinorelbine); olaparib/talazoparib if gBRCA; clinical trials; supportive and palliative care integrated early.
Am I a candidate for Paclitaxel / nab-paclitaxel, Olaparib, Talazoparib, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Bone-predominant disease and survivorship

For my situation (bone-predominant disease and survivorship), which of the standard options do you recommend and why?
Why: Guideline options include: Bisphosphonate or denosumab for bone metastases and AI-induced bone loss; adjuvant bisphosphonates in postmenopausal women; exercise, cardio-oncology, and adherence support.

Any stage

Are there clinical trials I could join, for example of Vepdegestrant, Sacituzumab tirumotecan, Datopotamab deruxtecan, ArteraAI Breast?
Why: Trials are how the next standard of care is set; asking early keeps options open.
Would a second opinion at a high-volume centre change anything, and can you help arrange it?
Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Why: Supportive care improves quality of life and helps patients complete treatment.
I read that “Late recurrence (up to 20+ years) with no predictive test”. How does that affect my plan?
Why: Open problems are where trials and second opinions matter most.
I read that “CDK4/6 resistance mechanisms and sequencing”. How does that affect my plan?
Why: Open problems are where trials and second opinions matter most.

Newly diagnosed? Read the first 60 days with HR-positive / HER2-negative breast cancer, then print the one-page appointment sheet with room for the answers.

Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.

Model panel1 model

Machine commentary by named AI models on a date, not clinical review. Claims are tied to the record's own sources; check them before relying on anything here.

FableAnthropic · v5.12026-09-17low confidence

The record's epidemiology and its account of adjuvant CDK4/6 inhibitors are consistent with the listed sources, and the treatment sequence it describes (endocrine plus CDK4/6 first, genotype-directed second line, ADCs before chemotherapy) hangs together. Most of what makes the record distinctive, however, cannot be checked against its three sources: the September 2026 camizestrant approval and advisory vote, the 2026 vepdegestrant and gedatolisib approvals, the ESMO-MCBS grades (which are attributed to an NCCN document that would not contain them), and the claim that HR-positive disease accounts for most breast cancer deaths. Internal problems include heavy duplication (Beatson, tamoxifen, palbociclib, TAILORx, HER2-low and 2026 each appear twice in the history; subtypes, biomarkers and stateOfArt repeat items; two separate 'metastatic first line' settings exist), inavolisib placed in both first and second line, the same NCCN URL used for both screening and treatment settings, and an unexplained 'spike' tag. Stage-based prognosis is absent.

Right 2Missing 1Unclear 5Show verdicts

Right
HR-positive disease makes up about 70% of the 2.3 million breast cancers diagnosed each year, and there are 670,000 annual breast cancer deaths.
The incidence and mortality totals match the GLOBOCAN 2022 figures given in the Wikipedia article, which also describes roughly 70% of breast cancers as oestrogen receptor-positive.
Wikipedia
Unclear
Because it can recur late, it accounts for the majority of the 670,000 annual breast cancer deaths.
None of the listed sources breaks breast cancer mortality down by receptor subtype. The claim is plausible given the subtype's share of cases, but the record cites nothing that quantifies it.
Wikipedia
Unclear
Since September 2026 camizestrant is switched in at molecular progression on emergent ESR1 mutation (SERENA-6; accelerated approval 4 Sep 2026), which the FDA endorsed over a negative advisory vote.
The record itself marks NCCN inclusion as pending, and none of the three listed sources documents a September 2026 approval or an advisory committee vote. The same applies to the 2026 vepdegestrant and gedatolisib approvals and the persevERA result; these rest on linked records rather than on any cited source.
Guideline (Screening and diagnosis)
Unclear
ESMO-MCBS grades such as 'A (monarchE); A (NATALEE)' and '4-5 (MONALEESA-2, -3, -7); 2 (PALOMA-2); 2 (MONARCH 3)' are given under version 'NCCN Guidelines: Breast Cancer'.
ESMO-MCBS scores are published by ESMO, not by NCCN. The cited PMC article is an NCCN document and would not carry these grades, so the scores cannot be checked against the record's own sources and appear to be attributed to the wrong document.
NCCN Guidelines: Breast Cancer (Early stage)
Unclear
Screening and diagnosis: mammography ± tomosynthesis; supplemental MRI for dense breasts or high risk, cited to NCCN 'Breast Cancer Screening'.
The URL given is the same one used for the treatment settings (category=1&id=1419). NCCN publishes screening and diagnosis as a separate guideline, so the reference as written does not clearly point to the document the guideline field names.
Guideline (Screening and diagnosis)
Unclear
Metastatic second line: genotype-directed capivasertib, inavolisib, alpelisib, everolimus.
Inavolisib is listed here as a second-line agent, but a later entry in the same record places it in first line for PIK3CA-mutant relapse on or within 12 months of adjuvant endocrine therapy (INAVO120), consistent with the trial described in the linked record. The two settings contradict each other and the cited NCCN document would need to be checked to settle placement.
NCCN Guidelines: Breast Cancer (Early stage)
Right
NCCN Category 1, preferred: adjuvant abemaciclib (monarchE) and ribociclib (NATALEE) in high-risk disease.
The cited NCCN document is the appropriate source for adjuvant CDK4/6 inhibitor recommendations and both agents carry category 1 listings in high-risk early disease. The 'preferred' qualifier and the exact eligibility criteria should be read against the specific guideline version, which the record does not name.
NCCN Guidelines: Breast Cancer (Early stage)
Missing
Prognosis and survival by stage for HR-positive / HER2-negative disease.
The record gives a single metastatic median overall survival figure (MONALEESA-2, 63.9 months) and no survival estimates for early-stage or node-positive disease, despite describing the disease as 'slow-evolving' and late-recurring. The Wikipedia article provides stage-based survival that could anchor this, and a cancer record should state expected outcomes.
Wikipedia

Human reviews sit on top of the panel. Add a clinical review or see the review queue.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Link cancer subtypes to their siblings and name parents i… · diff · file · history

Wikipedia

Breast cancer

Sources & links

Wikipedia